is tirzepatide bad for kidneys (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https 🥇 Tirzepatide and Kidneys: Risks

Reduce stress through exercise, meditation, or hobbies, as stress can worsen hair loss

Eli Lilly released phase 3 results from late-stage trials in 2025 and 2026, covering patients with Type 2 diabetes and obesity

The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising

doi: 10.1016/j.ejphar.2019.05.022 29